<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52420/2071-5943-2023-22-2-40-48</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-1226</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи | Original articles</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>PDCD4 и CDX-2 как иммуногистохимические маркеры атрофии слизистой оболочки желудка при хроническом гастрите</article-title><trans-title-group xml:lang="en"><trans-title>PDCD4 and CDX-2 as immunohistochemical markers of gastric mucosa atrophy in chronic gastritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1834-3629</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рубцов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rubtsov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вячеслав Александрович Рубцов − кандидат медицинских наук</p><p>Омск</p></bio><bio xml:lang="en"><p>Vjacheslav A. Rubtsov − Ph.D. in medicine</p><p>Omsk</p></bio><email xlink:type="simple">rubtsov.omgmu@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0949-8709</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шиманская</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shimanskaya</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Геннадьевна Шиманская − кандидат медицинских наук, доцент</p><p>Омск</p></bio><bio xml:lang="en"><p>Anna G. Shimanskaya − Ph.D. in medicine, Associate Professor</p><p>Omsk</p></bio><email xlink:type="simple">shimansckaya.anna@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8006-3260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парыгина</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Parygina</surname><given-names>М. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мария Николаевна Парыгина − кандидат медицинских наук</p><p>Омск</p></bio><bio xml:lang="en"><p>Marija N. Parygina − Ph.D. in medicine</p><p>Omsk</p></bio><email xlink:type="simple">mariyakern@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7200-7082</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мозговой</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Mozgovoi</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Игоревич Мозговой − доктор медицинских наук, доцент</p><p>Омск</p></bio><bio xml:lang="en"><p>Sergej I. Mozgovoi − Doctor of Science (Medicine), Associate Professor</p><p>Omsk</p></bio><email xlink:type="simple">simozgovoy@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9857-1674</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поморгайло</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pomorgailo</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Геннадьевна Поморгайло − доктор биологических наук, доцент</p><p>Омск</p></bio><bio xml:lang="en"><p>Elena G. Pomorgailo − Doctor of Science (Biology), Associate Professor</p><p>Omsk</p></bio><email xlink:type="simple">elenapom@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8607-7831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kononov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Владимирович Кононов − доктор медицинских наук, профессор</p><p>Омск</p></bio><bio xml:lang="en"><p>Aleksej V. Kononov − Doctor of Science (Medicine), Professor</p><p>Omsk</p></bio><email xlink:type="simple">ogmapath@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Омский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>04</month><year>2023</year></pub-date><volume>22</volume><issue>2</issue><fpage>40</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рубцов В.А., Шиманская А.Г., Парыгина М.Н., Мозговой С.И., Поморгайло Е.Г., Кононов А.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Рубцов В.А., Шиманская А.Г., Парыгина М.Н., Мозговой С.И., Поморгайло Е.Г., Кононов А.В.</copyright-holder><copyright-holder xml:lang="en">Rubtsov V.A., Shimanskaya A.G., Parygina М.N., Mozgovoi S.I., Pomorgailo E.G., Kononov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/1226">https://www.umjusmu.ru/jour/article/view/1226</self-uri><abstract><sec><title>Введение</title><p>Введение. Диагностика атрофии слизистой оболочки желудка представляет собой важную проблему, от решения которой зависит возможность осуществления вторичной профилактики рака желудка. Возможным путем решения выступает применение иммуногистохимических маркеров – белков, ассоциированных с клеточной перестройкой слизистой оболочки желудка, PDCD4 и CDX2.</p><p>Цель работы – оценка возможности использования иммуногистохимических маркеров PDCD4 и CDX-2 для диагностики атрофии слизистой оболочки желудка при хроническом гастрите, повышения информативности биопсийного исследования.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Объект исследования – 155 случаев биопсийного исследования слизистой оболочки желудка пациентов с хроническим гастритом (5 фрагментов на случай – 775 биоптатов). Была проведена сравнительная полуколичественная оценка иммуногистохимической экспрессии CDX2, PDCD4 при разных стадиях хронического гастрита. Для оценки корреляционной взаимосвязи использовался коэффициента корреляции Спирмена.</p></sec><sec><title>Результаты</title><p>Результаты. Статистически значимые отличия в уровне PDCD4 в исследуемых образцах в зависимости от стадии хронического гастрита отсутствовали, p=0,06. Статистически достоверное повышение индекс CDX2сумм при прогрессировании стадии хронического атрофического гастрита (р=0,005), продемонстрировало выраженную положительную корреляционную взаимосвязь r=0,70 (p&lt;0,01).</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Согласно полученным результатам, показано, что падение продукции белка PDCD4 не происходит при прогрессировании выраженности атрофии. Вспомогательное использование иммуногистохимического маркера CDX2 способно дать представление о наличии и выраженности как метапластических, так и абсолютных атрофических изменений слизистой оболочки желудка.</p></sec><sec><title>Заключение</title><p>Заключение. Одинаково высокий уровень индекса белка PDCD4 в слизистой оболочке желудка при различных стадиях хронического гастрита исключает возможность его использования в качестве иммуногистохимического маркера атрофии. Индекс полуколичественной иммуногистохимической оценки белка CDX2 может быть использован в качестве дополнительного маркера в системе поддержки принятия решений при оценке атрофических изменений в слизистой оболочке желудка.</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction Diagnosis of the gastric mucosa atrophy represents an important problem, the solution of which depends on the possibility of secondary prevention of gastric cancer. A possible way of solution is the use of immunohistochemical markers - proteins associated with cellular remodeling of gastric mucosa, PDCD4 and CDX2.</p><p>The aim of the work is to evaluate the possibility of using immunohistochemical markers PDCD4 and CDX-2 to diagnose atrophy of the gastric mucosa in chronic gastritis and increase the informative value of biopsy examination.</p><p>Materials and method The object of the study was 155 cases of biopsy examination of the gastric mucosa of patients with chronic gastritis (5 fragments per case − 775 biopsy specimens). A comparative semi-quantitative assessment of immunohistochemical expression of CDX2, PDCD4 at different stages of chronic gastritis was performed. Spearman correlation coefficient was used to assess correlation relationship.</p><p>Results There were no statistically significant differences in the level of PDCD4 in studied samples depending on the stage of chronic gastritis, p=0.06. Statistically significant increase of CDX2sum index in progressing stage of chronic atrophic gastritis (p=0.005), demonstrated a pronounced positive correlation r=0.70 (p&lt;0.01).</p><p>Discussion According to the results obtained, it is shown that the decline in PDCD4 protein does not occur with the progression of atrophy severity. Complementary use of immunohistochemical marker CDX2 is able to give an idea of the presence and severity of both metaplastic and absolute atrophic changes in the gastric mucosa.</p><p>Conclusion Equally high level of PDCD4 protein index in the gastric mucosa at different stages of chronic gastritis excludes the possibility of its use as an immunohistochemical marker of atrophy. Semi-quantitative immunohistochemical index of CDX2 protein can be used as an additional marker in decision support system for assessment of atrophic changes in gastric mucosa. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический гастрит</kwd><kwd>PDCD4</kwd><kwd>CDX2</kwd><kwd>атрофия слизистой оболочки желудка</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic gastritis</kwd><kwd>PDCD4</kwd><kwd>CDX2</kwd><kwd>gastric mucosa atrophy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 1988;83(5):504−509.</mixed-citation><mixed-citation xml:lang="en">Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 1988;83(5):504−509.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge M, Genta RM, Graham DY et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut 2016;65(5):721−725. https://doi.org/10.1136/gutjnl-2015-310846.</mixed-citation><mixed-citation xml:lang="en">Rugge M, Genta RM, Graham DY et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut 2016;65(5):721−725. https://doi.org/10.1136/gutjnl-2015-310846.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lash JG, Genta RM. Adherence to the sydney system guidelines increases the detection of helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013;38(4):424−431. https://doi.org/10.1111/apt.12383.</mixed-citation><mixed-citation xml:lang="en">Lash JG, Genta RM. Adherence to the sydney system guidelines increases the detection of helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013;38(4):424−431. https://doi.org/10.1111/apt.12383.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кононов А.В., Мозговой С.И., Поморгайло Е.Г. с соавт. Молекулярно-клеточные основы предикции рака желудка. Опыт мультидисциплинарного исследования. Уральский медицинский журнал 2017;148(4):9−18.</mixed-citation><mixed-citation xml:lang="en">Kononov AV, Mozgovoy SI, Pomorgailo EG et al. Molecular and cellular basis in prediction of gastric cancer: a multidisciplinary research experience. Ural medical journal 2017;148(4):9−18. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HY, Hu Y, Lu NH et al. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;12(1):1−12. https://doi.org/10.1080/19490976.2020.1809331.</mixed-citation><mixed-citation xml:lang="en">Chen HY, Hu Y, Lu NH et al. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;12(1):1−12. https://doi.org/10.1080/19490976.2020.1809331.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chawengsaksophak K. Cdx2 animal models reveal developmental origins of cancers. Genes (Basel) 2019;10(11):928. https://doi.org/10.3390/genes10110928.</mixed-citation><mixed-citation xml:lang="en">Chawengsaksophak K. Cdx2 animal models reveal developmental origins of cancers. Genes (Basel) 2019;10(11):928. https://doi.org/10.3390/genes10110928.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan T, Ni Z, Han C et al. SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia. Cancer Cell Int 2019;19:24. https://doi.org/10.1186/s12935-019-0739-8.</mixed-citation><mixed-citation xml:lang="en">Yuan T, Ni Z, Han C et al. SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia. Cancer Cell Int 2019;19:24. https://doi.org/10.1186/s12935-019-0739-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuhashi S, Manirujjaman M, Hamajima H et al. Control mechanisms of the tumor suppressor PDCD4: expression and functions. Int J Mol Sci 2019;20(9):2304. https://doi.org/10.3390/ijms20092304.</mixed-citation><mixed-citation xml:lang="en">Matsuhashi S, Manirujjaman M, Hamajima H et al. Control mechanisms of the tumor suppressor PDCD4: expression and functions. Int J Mol Sci 2019;20(9):2304. https://doi.org/10.3390/ijms20092304.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Biyanee A, Ohnheiser J, Singh P et al. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation. Oncogene 2015;34(11):1384−1392. https://doi.org/10.1038/onc.2014.83.</mixed-citation><mixed-citation xml:lang="en">Biyanee A, Ohnheiser J, Singh P et al. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation. Oncogene 2015;34(11):1384−1392. https://doi.org/10.1038/onc.2014.83.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li C, Deng L, Zhi Q et al. MicroRNA-183 functions as an oncogene by regulating pdcd4 in gastric cancer. anticancer agents. Med Chem 2016;16(4):447−455. https://doi.org/10.2174/1871520615666150914114237.</mixed-citation><mixed-citation xml:lang="en">Li C, Deng L, Zhi Q et al. MicroRNA-183 functions as an oncogene by regulating pdcd4 in gastric cancer. anticancer agents. Med Chem 2016;16(4):447−455. https://doi.org/10.2174/1871520615666150914114237.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chu J, Pelletier J. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim Biophys Acta 2015;1849(7):781−791. https://doi.org/10.1016/j.bbagrm.2014.09.006.</mixed-citation><mixed-citation xml:lang="en">Chu J, Pelletier J. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim Biophys Acta 2015;1849(7):781−791. https://doi.org/10.1016/j.bbagrm.2014.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40(8):650−658. https://doi.org/10.1016/j.dld.2008.02.030.</mixed-citation><mixed-citation xml:lang="en">Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40(8):650−658. https://doi.org/10.1016/j.dld.2008.02.030.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Способ формирования тканевых матриц для гистологического исследования: пат. 2711621 Рос. Федерация, №2018108688; заявл. 13.03.2018; опубл. 17.01.2020.</mixed-citation><mixed-citation xml:lang="en">Method of forming tissue matrices for histological examination: pat. 2711621 Russian Federation, №2018108688; appl. 13.03.2018; publ. 17.01.2020. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кононов А.В., Мозговой С.И., Шиманская А.Г. с соавт. Российский пересмотр классификации хронического гастрита: воспроизводимость оценки патоморфологической картины. Архив патологии 2011;73(4):52–56.</mixed-citation><mixed-citation xml:lang="en">Kononov AV, Mozgovoy SI, Shimanskaya AG et al. The Russian revision of chronic gastritis classification: reproducibility of the pathomorphologic picture. Pathology Archive = Arkhiv patologii 2011;73(4): 52–56. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Мозговой С.И. Алгоритм определения типа кишечной метаплазии слизистой оболочки желудка с помощью комбинированных гистохимических методов. Архив патологии 2009; 71(4):46−47.</mixed-citation><mixed-citation xml:lang="en">Mozgovoy SI. Algorithm for the determination of the type of intestinal metaplasia of the gastric mucosa by combined histochemical procedures. Pathology Archive = Arkhiv patologii 2009; 71(4):46−47. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Парыгина М.Н., Мозговой С.И., Шиманская А.Г. с соавт. Белок CDX2 как суррогатный маркер атрофии слизистой оболочки желудка. Журнал анатомии и гистопатологии 2021;10(3):60−67. https://doi.org/10.18499/2225-7357-2021-10-3-60-67.</mixed-citation><mixed-citation xml:lang="en">Parygina MN, Mozgovoi SI, Shimanskaya AG et al. CDX2 protein as a surrogate marker of gastric mucosal atrophy. Journal of Anatomy and Histopathology 2021;10(3):60−67. (In Russ.). https://doi.org/10.18499/2225-7357-2021-10-3-60-67.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Способ полуколичественной оценки белка PDCD4 иммуногистохимическим методом: пат. 2706005 Рос. Федерация, №2018135219; заявл. 04.10.2018; опубл. 13.11.2019.</mixed-citation><mixed-citation xml:lang="en">Method for semiquantitative evaluation of PDCD4 protein by immunohistochemical method: pat. 2706005 Russian Federation, №2018135219; appl. 04.10.2018; publ. 13.11.2019. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge M, Genta RM. Gastric cancer prevention: Merging future hopes, with present clinical practice. J Surg Oncol 2022;126(4):838−839. https://doi.org/10.1002/jso.26997.</mixed-citation><mixed-citation xml:lang="en">Rugge M, Genta RM. Gastric cancer prevention: Merging future hopes, with present clinical practice. J Surg Oncol 2022;126(4):838−839. https://doi.org/10.1002/jso.26997.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao ZY, Ru Y, Sun JT et al. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Asian Pac J Cancer Prev 2012;13(1):247−250. https://doi.org/10.7314/apjcp.2012.13.1.247.</mixed-citation><mixed-citation xml:lang="en">Xiao ZY, Ru Y, Sun JT et al. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Asian Pac J Cancer Prev 2012;13(1):247−250. https://doi.org/10.7314/apjcp.2012.13.1.247.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Ma L, Shi D et al. Prognostic significance of miR-21 and PDCD4 in patients with stage II esophageal carcinoma after surgical resection. J Cell Biochem 2018;119(6):4783−4791. https://doi.org/10.1002/jcb.26672.</mixed-citation><mixed-citation xml:lang="en">Zhang J, Ma L, Shi D et al. Prognostic significance of miR-21 and PDCD4 in patients with stage II esophageal carcinoma after surgical resection. J Cell Biochem 2018;119(6):4783−4791. https://doi.org/10.1002/jcb.26672.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann J, Heinemann V, Engel J et al. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. Virchows Arch 2018;473(2):199−207. https://doi.org/10.1007/s00428-018-2360-y.</mixed-citation><mixed-citation xml:lang="en">Neumann J, Heinemann V, Engel J et al. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. Virchows Arch 2018;473(2):199−207. https://doi.org/10.1007/s00428-018-2360-y.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar BE, Pérez-Cala T, Gomez-Villegas SI et al. The OLGA-OLGIM staging and the interobserver agreement for gastritis and preneoplastic lesion screening: a cross-sectional study. Virchows Arch 2022;480(4):759−769. https://doi.org/10.1007/s00428-022-03286-8.</mixed-citation><mixed-citation xml:lang="en">Salazar BE, Pérez-Cala T, Gomez-Villegas SI et al. The OLGA-OLGIM staging and the interobserver agreement for gastritis and preneoplastic lesion screening: a cross-sectional study. Virchows Arch 2022;480(4):759−769. https://doi.org/10.1007/s00428-022-03286-8.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Robertson S, Patil DT. An update on the role of immunohistochemistry in the evaluation of gastrointestinal tract disorders. Adv Anat Pathol 2020;27(3):193−205. https://doi.org/10.1097/PAP.0000000000000214.</mixed-citation><mixed-citation xml:lang="en">Robertson S, Patil DT. An update on the role of immunohistochemistry in the evaluation of gastrointestinal tract disorders. Adv Anat Pathol 2020;27(3):193−205. https://doi.org/10.1097/PAP.0000000000000214.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ferris WF. The role and interactions of programmed cell death 4 and its regulation by microRNA in transformed cells of the gastrointestinal tract. Front Oncol 2022;12:903374. https://doi.org/10.3389/fonc.2022.903374.</mixed-citation><mixed-citation xml:lang="en">Ferris WF. The role and interactions of programmed cell death 4 and its regulation by microRNA in transformed cells of the gastrointestinal tract. Front Oncol 2022;12:903374. https://doi.org/10.3389/fonc.2022.903374.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Рубцов В.А., Поморгайло Е.Г., Кононов А.В. Регуляторный белок PDCD4 в тканях слизистой оболочки желудка при хроническом гастрите и раке желудка. Уральский медицинский журнал 2019;178(10):59−62. https://doi.org/10.25694/URMJ.2019.10.14.</mixed-citation><mixed-citation xml:lang="en">Rubtsov VA, Pomorgailo EG, Kononov AV. PDCD4 regulatory protein in tissue gastric mucosa in chronic gastritis and stomach cancer. Ural medical journal 2019;178(10):59−62. (In Russ.). https://doi.org/10.25694/URMJ.2019.10.14.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rong B, Chen X, Xie G et al. Gastric cancer growth modulated by circSNTB2/miR-6938-5p/G0S2 and PDCD4. Comb Chem High Throughput Screen 2022. https://doi.org/10.2174/1386207326666221108112113.</mixed-citation><mixed-citation xml:lang="en">Rong B, Chen X, Xie G et al. Gastric cancer growth modulated by circSNTB2/miR-6938-5p/G0S2 and PDCD4. Comb Chem High Throughput Screen 2022. https://doi.org/10.2174/1386207326666221108112113.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Koide T, Koyanagi-Aoi M, Uehara K et al. CDX2-induced intestinal metaplasia in human gastric organoids derived from induced pluripotent stem cells. iScience 2022;25(5):104314. https://doi.org/10.1016/j.isci.2022.104314.</mixed-citation><mixed-citation xml:lang="en">Koide T, Koyanagi-Aoi M, Uehara K et al. CDX2-induced intestinal metaplasia in human gastric organoids derived from induced pluripotent stem cells. iScience 2022;25(5):104314. https://doi.org/10.1016/j.isci.2022.104314.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HY, Hu Y, Xu XB et al. Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2. Helicobacter 2021;26(6):e12849. https://doi.org/10.1111/hel.12849.</mixed-citation><mixed-citation xml:lang="en">Chen HY, Hu Y, Xu XB et al. Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2. Helicobacter 2021;26(6):e12849. https://doi.org/10.1111/hel.12849.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Yagi K, Tsuchiya A, Hashimoto S et al. Pyloric-gland metaplasia may be an origin of cancer and intestinal metaplasia with possible CDX2 expression. Gastroenterol Rep (Oxf) 2020;9(4):370−373. https://doi.org/10.1093/gastro/goaa061.</mixed-citation><mixed-citation xml:lang="en">Yagi K, Tsuchiya A, Hashimoto S et al. Pyloric-gland metaplasia may be an origin of cancer and intestinal metaplasia with possible CDX2 expression. Gastroenterol Rep (Oxf) 2020;9(4):370−373. https://doi.org/10.1093/gastro/goaa061.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HY, Hu Y, Lu NH, et al. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;9;12(1):1−12. https://doi.org/10.1080/19490976.2020.1809331.</mixed-citation><mixed-citation xml:lang="en">Chen HY, Hu Y, Lu NH, et al. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;9;12(1):1−12. https://doi.org/10.1080/19490976.2020.1809331.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
